Eisai Announces New Research at the 2017 Alzheimer's Association International Conference® (AAIC®)

WOODCLIFF LAKE, N.J., July 17, 2017 /PRNewswire/ -- Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease portfolio, at the Alzheimer's Association International Conference® (AAIC®) 2017 in London from July 16-20, 2017. In addition, Eisai will host a symposium discussing BACE inhibition as a therapeutic target for Alzheimer's disease on Monday, July 17th. AAIC is the premier annual conference for presentation and discussion of the latest Alzheimer's and dementia research.

Eisai logo. (PRNewsFoto/Eisai Inc.)

"The data being presented at the AAIC demonstrate our commitment to people living with Alzheimer's disease and dementia as well as the healthcare providers who care for these patients," said Lynn Kramer, M.D., Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai.  

The following data will be presented by Eisai at this year's AAIC:

Abstract Name




Elenbecestat, a novel oral BACE inhibitor, has no clinically meaningful effect on QTc interval up to a supratherapeutic dose of 200mg

Date: July 16

9:30-4:15 pm


Abstract 19055

Elenbecestat pharmacokinetic drug-drug interactions indicated no dosage adjustments required for most concomitant treatments

Date: July 17

9:30-4:45 pm


Abstract ID 19157

Preclinical studies with elenbecestat, a novel BACE inhibitor, show no evidence of hypopigmentation

Date: July 18


Abstract ID: 18045



Pharmacologic characterization of BAN2401-mediated Aβ protofibril clearance by microglia

Date: July 17

9:30-4:45 pm


Abstract ID 19125



Population pharmacokinetic-pharmacodynamic (PPK/PD) modeling of E2027, a selective phosphodiesterase-9 inhibitor, following single ascending oral doses in healthy volunteers

Date: July 16

9:30-4:15 pm


Abstract ID: 17550

Phase 1 investigation into the safety, tolerability, pharmacokinetics and pharmacodynamics of E2027, a selective phosphodiesterase-9 (PDE9) inhibitor


Date: July 17

9:30-4:45 pm


Abstract ID 17712

Preclinical characterization of E2027, a novel phosphodiesterase 9 inhibitor

Date: July 18

9:30-4:15 pm


Abstract ID: 17832



The financial capacity instrument (FCI): short form is a novel, performance-based measure that may help differentiate mild cognitive impairment and mild dementia due to Alzheimer's Disease populations in clinical trials

Date: July 16

9:30-4:45 pm


Abstract ID 18497

Elenbecestat and BAN2401 are being jointly developed by Eisai and Biogen.

This release discusses investigational agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that these investigational agents will successfully complete clinical development or gain FDA approval.

About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.



Media Inquiries

Investor Inquiries

Laurie Landau

Ivor Macleod

Eisai Inc.

Eisai Inc.





SOURCE Eisai Inc.

Type Press Release

Date Released July 17, 2017

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields